FDA (Drugs) recall action 69152
The FDA (Drugs) publishes a recall like this one as 118 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 118 pages.
Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.
The agency’s own wording, quoted from the enforcement report.
The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.
Martin Avenue Pharmacy is voluntarily recalling Acetylcysteine 10% inhalant solution due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Bupivacaine hydrochloride 0.25% injectable vials due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Tri-mix T102 injectable vials because quality control issues identified during an FDA inspection may compromise sterility.
Martin Avenue Pharmacy is voluntarily recalling compounded sterile preparations due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Tri-mix injectable vials because quality control observations during an FDA inspection raised concerns about sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Cromolyn sodium 1% inhalant solution due to sterility assurance concerns identified during an FDA inspection.
Martin Avenue Pharmacy is voluntarily recalling compounded sterile preparations, including Hyaluronidase base vehicle, due to quality control issues affecting sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling compounded sterile preparations, including PGE 1, due to quality control observations that risk sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling compounded sterile preparations, including morphine/bupivacaine, due to quality control issues affecting sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling all compounded sterile preparations within expiry due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Glycerin 72% sodium chloride injectable vials due to quality control observations that risk sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Atropine sulfate 0.01% ophthalmic solution due to quality control issues that may compromise sterility.
Martin Avenue Pharmacy is voluntarily recalling compounded sterile preparations, including triamcinolone acetonide, due to quality control observations that risk sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling all compounded sterile preparations within expiry due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Lidocaine 2% injectable vials because quality control observations during an FDA inspection raised concerns about sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling PGE 4 injectable vials because quality control issues identified during an FDA inspection present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling veterinary injection suspensions due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling compounded sterile preparations, including hydromorphone/clonidine/bupivacaine, due to quality control observations that risk sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Histamine 0.55 mg/mL injectable vials because quality control observations during an FDA inspection raised concerns about sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Tri-mix injectable vials due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Quad Mix injectable vials due to quality control observations that present a risk to sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling Tri-mix ST2 injectable vials because quality control issues identified during an FDA inspection may compromise sterility.
Martin Avenue Pharmacy is voluntarily recalling Phenylephrine 1% injectable vials because quality control issues may compromise sterility assurance.
Martin Avenue Pharmacy is voluntarily recalling compounded hydromorphone and bupivacaine injections due to quality control issues that may compromise sterility.
Martin Avenue Pharmacy is voluntarily recalling Tri-mix T25 injectable vials because quality control observations during an FDA inspection presented a risk to sterility assurance.